Transcranial Direct Current Stimulation in Children with Autism Spectrum Disorder
Launched by THE HONG KONG POLYTECHNIC UNIVERSITY · Mar 11, 2025
Trial Information
Current as of May 09, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a treatment called Transcranial Direct Current Stimulation (tDCS) for children with Autism Spectrum Disorder (ASD). tDCS is a safe method that uses a gentle electrical current to stimulate specific parts of the brain, and it may help improve thinking and behavior in children with ASD. In this trial, researchers will look at how effective tDCS is when combined with cognitive training exercises over ten consecutive days. They will compare the results of children receiving the actual tDCS treatment to those receiving a "sham" (fake) treatment to see if it really makes a difference.
To participate in the study, children must be between 8 and 12 years old, have a diagnosis of ASD, and be able to communicate in Chinese. They should also have an IQ above 60. Children with serious motor difficulties or a history of other neurological or psychiatric issues will not be eligible. Participants will receive 20-minute sessions of tDCS along with cognitive training and will undergo some tests before and after the treatment to measure any changes. This study aims to better understand how tDCS affects cognitive skills and the brain's function in children with ASD, which could help in developing future treatments.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • being 8-12 years old
- • diagnosed with ASD given by registered psychiatrists or clinical psychologists according to the Diagnostic and Statistical Manual of Mental Disorders-5th Edition (DSM-5) criteria of ASD
- • IQ score above 60
- • able to communicate in Chinese
- Exclusion Criteria:
- • with severe motor dysfunctions
- • history of other neurological and psychiatric disorders or head trauma
About The Hong Kong Polytechnic University
The Hong Kong Polytechnic University (PolyU) is a leading institution in applied research and education, dedicated to advancing knowledge and innovation in various fields, including health sciences. As a clinical trial sponsor, PolyU focuses on conducting rigorous and ethically sound research to enhance understanding of medical interventions and improve patient outcomes. The university leverages its multidisciplinary expertise, state-of-the-art facilities, and collaboration with industry partners to facilitate groundbreaking studies that address pressing health challenges. Committed to fostering an environment of academic excellence, PolyU aims to translate research findings into practical solutions that benefit society and contribute to the global advancement of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hung Hom, Kowloon, Hong Kong
Patients applied
Trial Officials
Yvonne Han, PhD
Principal Investigator
The Hong Kong Polytechnic University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported